A intently watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in considered one of three late-stage trials.
The drug, milvexian, is a selective issue XIa inhibitor designed to stop dangerous clotting within the blood. It’s being examined in three Part 3 trials, in instances of acute coronary syndrome, and to handle atrial fibrillation and forestall secondary strokes. BMS reported Friday that it’s shutting down the primary trial, for acute coronary syndrome.
Acute coronary syndrome is an umbrella time period for conditions wherein blood circulation to the guts muscle all of the sudden drops as a result of components like a clot or coronary heart assault. BMS reported that an interim evaluation confirmed milvexian is unlikely to fulfill the first endpoint of the trial.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.